Bladder Cancer Weekly

November 11, 2024

Videos

Peer-to-Peer Clinical Conversations

BRAVO Trial Highlights Improved Detection Reduces Bladder Cancer Recurrence - Ali Nasrallah

Ali Nasrallah

Ali Nasrallah discusses the BRAVO study (Bladder Cancer Recurrence Analysis in Veterans and Outcomes).

View

Bridging Evidence to Practice: Bladder Cancer Therapy Guidelines and Global Implementation - Andrea Apolo

Andrea B. Apolo

Ashish Kamat talks with Andrea Apolo about implementing new treatment standards in bladder cancer, focusing on the recent EV-302 and CheckMate-901 trials.

View

Beyond the Abstracts

Histopathological, Molecular and Clinical Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder (LELC-B) - Beyond the Abstract

Conference Coverage

ASTRO 2024: Bladder Cancer - The Dawn or Era of More Personalized Radiotherapy

ASTRO 2024: Bladder Adjuvant RadioTherapy (BART): Acute and Late Toxicity from a Phase III Multicenter Randomized Controlled Trial

ASTRO 2024: Bladder Preservation - A Modern Choice for Patients

ESMO 2024: Empowering Bladder Cancer Care Integrating Patient Preferences and Voices

ESMO 2024: JCOG1019 Phase III Study Comparing the Effectiveness of Watchful Waiting and Intravesical BCG in Patients with High-grade pT1 Bladder Cancer with pT0 on the 2nd Transurethral Resection Specimen

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

A novel approach to engineering three-dimensional bladder tumor models for drug testing.

A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy.

Prognostic value of neutrophil-to-lymphocyte ratio in patients with non-muscle-invasive bladder cancer with intravesical Bacillus Calmette-Guérin immunotherapy: a systematic review and meta-analysis.

The role of re-transurethral resection of bladder tumor in patients with TaHG non muscle invasive bladder cancer.

Prospective Assessment of VI-RADS with Muscle Invasion in Urinary Bladder Cancer and Its Implication on Re-Resection/Restaging TURBT Patients.

DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial.

Smoking behavior and the risks of tumor recurrence and progression in patients with non-muscle-invasive bladder cancer.

Evaluating the Clinical Impact of Ureteral Frozen Section Analysis During Radical Cystectomy: A Single-Center Retrospective Study.

Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non-muscle-invasive bladder cancer using multi-layered -omics studies.

A Molecular Urine Assay to Detect Recurrences During Surveillance of High-Risk Non-Muscle Invasive Bladder Cancer.

Prototol for the Prospective Sample Collection for Cancer of Bladder (ProCaB) Trial by the Cancer of the Bladder Leuven (CaBLe) Consortium.

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study.

Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer.

Lifestyle Advice to Patients with Bladder Cancer: A National Survey of Dutch Urologists.

Perioperative Use of ctDNA to Guide Treatment for Urothelial Carcinoma: The Future is Now.

Single-Cell Transcriptomic Analysis to Build a Microenvironment-Aware Bladder Cancer Prognostic Model - Expert Commentary

MTAP Protein Status Is Highly Concordant with CDKN2A Fluorescent in Situ Hybridization and Allows Stratification of the Luminal Subtype in Muscle-Invasive Bladder Cancer - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login